Literature DB >> 16641468

Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers.

Angela Sansone-Parsons1, Gopal Krishna, Angela Calzetta, David Wexler, Bhavna Kantesaria, Mitchell A Rosenberg, Marc A Saltzman.   

Abstract

We conducted a randomized, crossover study in healthy adults to examine the effects of a nutritional supplement (Boost Plus) on posaconazole pharmacokinetics. In this study, coadministration of posaconazole with Boost Plus increased the maximum concentration of posaconazole in serum and area under the concentration-time curve from 0 to 72 h values 3.4- and 2.6-fold, respectively, compared to those for the fasted state.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16641468      PMCID： PMC1472190          DOI： 10.1128/AAC.50.5.1881-1883.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Refractory coccidioidomycosis treated with posaconazole.

Authors:  Gregory M Anstead; Gavin Corcoran; James Lewis; Deborah Berg; John R Graybill
Journal:  Clin Infect Dis       Date:  2005-05-13       Impact factor: 9.079

2.  Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

3.  In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes.

Authors:  Qiu N Sun; Annette W Fothergill; Dora I McCarthy; Michael G Rinaldi; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

4.  Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

5.  Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease.

Authors:  R Courtney; A Sansone; W Smith; T Marbury; P Statkevich; M Martinho; M Laughlin; S Swan
Journal:  J Clin Pharmacol       Date:  2005-02       Impact factor: 3.126

6.  Disposition of posaconazole following single-dose oral administration in healthy subjects.

Authors:  Philip Krieter; Brian Flannery; Timothy Musick; Mark Gohdes; Monika Martinho; Rachel Courtney
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  In vitro susceptibilities of zygomycetes to conventional and new antifungals.

Authors:  Eric Dannaoui; Joseph Meletiadis; Johan W Mouton; Jacques F G M Meis; Paul E Verweij
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

8.  Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study.

Authors:  D Wexler; R Courtney; W Richards; C Banfield; J Lim; M Laughlin
Journal:  Eur J Pharm Sci       Date:  2004-04       Impact factor: 4.384

9.  Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.

Authors:  Rachel Courtney; David Wexler; Elaine Radwanski; Josephine Lim; Mark Laughlin
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

10.  Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.

Authors:  D J Diekema; S A Messer; R J Hollis; R N Jones; M A Pfaller
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948
View more
  32 in total

Review 1.  Triazole antifungal agents in invasive fungal infections: a comparative review.

Authors:  Cornelia Lass-Flörl
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

2.  Relevance of timing for determination of posaconazole plasma concentrations.

Authors:  Werner J Heinz; Janina Zirkel; Anna Kuhn; Diana Schirmer; Ulrike Lenker; Daniela Keller; Hartwig Klinker
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

3.  Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects.

Authors:  Wendy M Kersemaekers; Thijs van Iersel; Ulla Nassander; Edward O'Mara; Hetty Waskin; Maria Caceres; Marlou L P S van Iersel
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

Review 4.  Pharmacokinetic/pharmacodynamic profile of posaconazole.

Authors:  Yanjun Li; Ursula Theuretzbacher; Cornelius J Clancy; M Hong Nguyen; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

5.  Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation.

Authors:  Wendy M Kersemaekers; Peter Dogterom; Jialin Xu; Eugene E Marcantonio; Rik de Greef; Hetty Waskin; Marlou L P S van Iersel
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

6.  Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method.

Authors:  Werner Christian Neubauer; Monika Engelhardt; Armin König; Stefanie Hieke; Manfred Jung; Hartmut Bertz; Klaus Kümmerer
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

7.  Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.

Authors:  Gopal Krishna; Allen Moton; Lei Ma; Matthew M Medlock; James McLeod
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

8.  Zygomycosis: an emerging fungal infection with new options for management.

Authors:  Carol A Kauffman; Anurag N Malani
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

9.  Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Santiago Grau; Rafael Cámara; Manuel Jurado; Jaime Sanz; Belén Aragón; Irmina Gozalbo
Journal:  Eur J Health Econ       Date:  2017-05-31

Review 10.  Posaconazole : a review of its use in the prophylaxis of invasive fungal infections.

Authors:  James E Frampton; Lesley J Scott
Journal:  Drugs       Date:  2008       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.